Filing Flows › Halozyme Therapeutics (HALO) › Capital expenditures
Halozyme Therapeutics (HALO) capital expenditures by quarter
Halozyme Therapeutics' capital expenditures were $3.0M in Q3 2026 (third quarter 2026), -27% from Q2 2026. Over the last 7 quarters it ranged from $950K (Q1 2025) to $4.2M (Q2 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $3.0M | -27% | +0.7% |
| Q2 2026 | $4.2M | +12% | +167% |
| Q1 2026 | $3.7M | +162% | +294% |
| Q4 2025 | $1.4M | -53% | — |
| Q3 2025 | $3.0M | +94% | — |
| Q2 2025 | $1.6M | +65% | — |
| Q1 2025 | $950K | — | — |
Q3 2026 at a glance
Halozyme Therapeutics, Q3 2026: revenue $493M (+39% year over year), operating margin 59.8%, net earnings $247M, operating cash flow $258M. The chart follows the revenue to costs, profit and cash.
Questions
What is Halozyme Therapeutics' capital expenditures?
Halozyme Therapeutics' capital expenditures were $3.0M in Q3 2026 (third quarter 2026), -27% from Q2 2026.
How has Halozyme Therapeutics' capital expenditures changed?
Over the last 7 quarters it ranged from $950K (Q1 2025) to $4.2M (Q2 2026).